Prostate Cancer Clinical Trials in Maryland

Showing 341-360 of 384 trials

Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer

NCT00045227

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of vaccine therapy with or without docetaxel in treating patients who have metastatic prostate cancer.

Prostate Cancer

National Cancer Institute (NCI)Started Aug 2002

Bethesda, Maryland, United States

TERMINATEDPhase 317 miles

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

NCT00450970

The SPERA trial is designed to 1. provide satraplatin to physicians with patients who have hormone refractory prostate cancer (HRPC) which has progressed following unlimited cytotoxic chemotherapy regimens for metastatic disease and 2. to evaluate the safety of oral satraplatin in this patient population.

Prostate Cancer

Agennix344 participantsStarted Feb 2007

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Homewood, Alabama, United States +118 more locations

Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)

Prostate Cancer Trials in Other Cities

Internet-Based Education for Prostate Cancer Screening

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

Other Conditions in Maryland